
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie's strong financial outlook is supported by an increase in 2025 guidance for both global sales and earnings per share, with management projecting neuroscience segment sales to reach approximately $10.7 billion and adjusted EPS to range between $12.09 and $12.29. The company's recent quarterly performance surpassed expectations, bolstered by robust contributions from key products in their immunology and oncology franchises, including Skyrizi and Rinvoq, while also benefiting from advancements in neuroscience with contributions from Vraylar and Botox Therapeutic. Additionally, AbbVie's strategic acquisitions of Cerevel and ImmunoGen, alongside its established portfolio from the Allergan acquisition, position the firm for sustained growth and resilience in an evolving pharmaceutical landscape.
Bears say
AbbVie's stock faces multiple downside risks, primarily stemming from disappointing commercial execution across key products such as Skyrizi, Rinvoq, and Botox, which could hinder revenue growth. Furthermore, the company's heavy reliance on Humira may result in greater than expected sales erosion due to increasing market share of launched biosimilars, compounded by pressure from competitors in oncology and limited market penetration in neuroscience. Additionally, macroeconomic challenges impacting consumer spending, particularly within the Aesthetics segment, and pipeline uncertainties further contribute to a negative outlook for AbbVie’s financial performance.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares